Lyell Immunopharma/$LYEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lyell Immunopharma
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Ticker
$LYEL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
300
ISIN
US55083R1041
Website
LYEL Metrics
BasicAdvanced
$125M
-
-$1.23
-0.26
-
Price and volume
Market cap
$125M
Beta
-0.26
52-week high
$2.85
52-week low
$0.39
Average daily volume
673K
Financial strength
Current ratio
7.489
Quick ratio
7.295
Long term debt to equity
14.516
Total debt to equity
16.964
Management effectiveness
Return on assets (TTM)
-24.40%
Return on equity (TTM)
-71.20%
Valuation
Price to revenue (TTM)
1,767.364
Price to book
0.37
Price to tangible book (TTM)
0.37
Price to free cash flow (TTM)
-0.653
Growth
Revenue change (TTM)
-4.41%
Earnings per share change (TTM)
35.96%
3-year revenue growth (CAGR)
-80.49%
3-year earnings per share growth (CAGR)
-3.42%
What the Analysts think about LYEL
Analyst ratings (Buy, Hold, Sell) for Lyell Immunopharma stock.
LYEL Financial Performance
Revenues and expenses
LYEL Earnings Performance
Company profitability
LYEL News
AllArticlesVideos
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
GlobeNewsWire·1 week ago
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
GlobeNewsWire·1 month ago
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lyell Immunopharma stock?
Lyell Immunopharma (LYEL) has a market cap of $125M as of May 23, 2025.
What is the P/E ratio for Lyell Immunopharma stock?
The price to earnings (P/E) ratio for Lyell Immunopharma (LYEL) stock is 0 as of May 23, 2025.
Does Lyell Immunopharma stock pay dividends?
No, Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Lyell Immunopharma dividend payment date?
Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Lyell Immunopharma?
Lyell Immunopharma (LYEL) has a beta rating of -0.26. This means that it has an inverse relation to market volatility.